PATRYS LIMITED - Announcements

Market Cap $14.40M Add to my watchlist

Healthcare Biotechnology

Patrys Limited is an Australia-based company, which is focused on the development of its... Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

PAB	Change in substantial holding		20/02/18	864.06KB	Share
PAB	Section 708A Cleansing Notice and Appendix 3B		16/02/18	886.27KB	Share
PAB	PAB Successfully Completes Rights Issue - Raises $2.4M		16/02/18	163.46KB	Share
PAB	Rights Issue Closes Oversubscribed		14/02/18	101.55KB	Share
PAB	Entitlement Offer Documents		02/02/18	96.85KB	Share
PAB	Appendix 4C - Quarterly - 31 December 2017	PRICE SENSITIVE	31/01/18	306.28KB	Share
PAB	Publication and Patent Filing for Humanized Version of 3E10	PRICE SENSITIVE	30/01/18	144.28KB	Share
PAB	PAT-DX1-NP Localizes to Lymph Node Metastases	PRICE SENSITIVE	29/01/18	235.72KB	Share
PAB	PAT-DX1 Targets Nanoparticles to Breast Cancer	PRICE SENSITIVE	29/01/18	235.96KB	Share
PAB	Despatch of Entitlement Issue Offer Documents		22/01/18	1.85MB	Share
PAB	Letter to Ineligible Shareholders - Entitlement Offer		16/01/18	96.98KB	Share
PAB	Letter to Shareholders - Entitlement Offer		16/01/18	73.15KB	Share
PAB	Letter to Option Holders - Entitlement Offer		15/01/18	97.61KB	Share
PAB	Notice under Section 708AA(2)(F) - Entitlement Offer		15/01/18	186.32KB	Share
PAB	Appendix 3B - Entitlement Offer		15/01/18	529.52KB	Share
PAB	Entitlement Offer Booklet	PRICE SENSITIVE	15/01/18	1.79MB	Share
PAB	Corporate Overview		15/01/18	1.29MB	Share
PAB	$2.4 Million Fully Underwritten Rights Issue	PRICE SENSITIVE	15/01/18	151.14KB	Share
PAB	Trading Halt	PRICE SENSITIVE	11/01/18	491.31KB	Share
PAB	Appendix 3B - Correction		10/01/18	602.44KB	Share
PAB	NDF Research - Initiation of Coverage		19/12/17	327.61KB	Share
PAB	PAT-DX1 is synergistic with PARP inhibitor	PRICE SENSITIVE	11/12/17	242.61KB	Share
PAB	Results of Annual General Meeting		23/11/17	409.41KB	Share
PAB	Chairman's Address and CEO Presentation to 2017 AGM		23/11/17	2.57MB	Share
PAB	Change in substantial holding		17/11/17	1.15MB	Share
PAB	Collaboration with WEHI	PRICE SENSITIVE	16/11/17	237.83KB	Share
PAB	Appendix 4C - Quarterly - 30 September 2017	PRICE SENSITIVE	27/10/17	200.91KB	Share
PAB	Notice of Annual General Meeting/Proxy Form		23/10/17	829.23KB	Share
PAB	Patrys Deoxymab Video Replacement		18/10/17	117.02KB	Share
PAB	Patrys Video Explaining Deoxymab 3E10 Mechanism of Action		18/10/17	662.83KB	Share
PAB	PAB and Garvan Institute of Medical Research Awarded Grant	PRICE SENSITIVE	16/10/17	685.46KB	Share
PAB	US Patent Granted for Preclinical Candidate PAT-LM1	PRICE SENSITIVE	11/10/17	543.76KB	Share
PAB	PAB Business Review - 30 June 2017		25/09/17	1.19MB	Share
PAB	PAT-DX1 Conjugated to Nanoparticles, Targets Tumors	PRICE SENSITIVE	18/09/17	231.85KB	Share
PAB	PAT-DX1 Active in Pre-clinical Cancer Models	PRICE SENSITIVE	14/09/17	242.9KB	Share
PAB	Appendix 4G and Corporate Governance Statement		29/08/17	868.5KB	Share
PAB	Appendix 4E and 2017 Annual Report	PRICE SENSITIVE	29/08/17	1.08MB	Share
PAB	Appendix 4C - Quarterly - 30 June 2017	PRICE SENSITIVE	26/07/17	580.52KB	Share
PAB	Change in substantial holding		25/07/17	131.87KB	Share
PAB	Section 708A Cleansing Notice and Appendix 3B		17/07/17	911.13KB	Share
PAB	Patrys' Deoxymab 3E10 patent granted in the U.S.	PRICE SENSITIVE	12/07/17	461.81KB	Share
PAB	PAB Licences Deoxymab 3E10 - nanoparticle IP from Yale	PRICE SENSITIVE	13/06/17	247.59KB	Share
PAB	Investor Update		08/06/17	708.93KB	Share
PAB	Finance Update	PRICE SENSITIVE	01/05/17	323.74KB	Share
PAB	Appendix 4C - Quarterly - 31 March 2017	PRICE SENSITIVE	27/04/17	172.38KB	Share
PAB	Appendix 3B - Issue of Unlisted Options		19/04/17	506.06KB	Share
PAB	Deoxymab 3E10 lead candidate confirmed	PRICE SENSITIVE	19/04/17	116.16KB	Share
PAB	Change in substantial holding		31/03/17	1.02MB	Share
PAB	Appendix 4D - Half Year Accounts - 31 December 2016	PRICE SENSITIVE	23/02/17	1.13MB	Share
PAB	Appendix 4C - Quarterly - 31 December 2016	PRICE SENSITIVE	17/01/17	170.29KB	Share
PAB	Change of Director's Interest Notice		22/12/16	195.54KB	Share
PAB	Change of Director's Interest Notice		20/12/16	194.48KB	Share
PAB	Appendix 3B		20/12/16	525.82KB	Share
PAB	Final share buy-back notice - Appendix 3F		19/12/16	253.92KB	Share
PAB	Daily share buy-back notice - Appendix 3E		19/12/16	225.49KB	Share
PAB	Announcement of buy-back - Appendix 3C		16/12/16	240.77KB	Share
PAB	Appointments to new Scientific Advisory Board		13/12/16	109.14KB	Share
PAB	Results of Annual General Meeting		24/11/16	128.43KB	Share
PAB	2016 AGM Presentation		24/11/16	2.58MB	Share
PAB	Appendix 4C - Quarterly - 30 September 2016-PAB.AX	PRICE SENSITIVE	28/10/16	285.35KB	Share
PAB	Response to ASX Price Query-PAB.AX	PRICE SENSITIVE	27/10/16	601.55KB	Share
PAB	Notice of Annual General Meeting/Proxy Form-PAB.AX		24/10/16	965.34KB	Share
PAB	PAB Business Review - 30 June 2016-PAB.AX		26/09/16	896.72KB	Share
PAB	Market Update-PAB.AX	PRICE SENSITIVE	13/09/16	447.92KB	Share
PAB	Appendix 4G and Corporate Governance Statement-PAB.AX		30/08/16	405.92KB	Share
PAB	Appendix 4E and 2016 Annual Report-PAB.AX	PRICE SENSITIVE	30/08/16	810.06KB	Share
PAB	Appendix 4C - Quarterly - 30 June 2016-PAB.AX	PRICE SENSITIVE	28/07/16	100.42KB	Share
PAB	Change of Director's Interest Notices x2-PAB.AX		26/05/16	46.72KB	Share
PAB	Appendix 4C - Quarterly - 31 March 2016-PAB.AX	PRICE SENSITIVE	21/04/16	183.73KB	Share
PAB	Publication on PAT-SM6 Combination Therapy-PAB.AX	PRICE SENSITIVE	05/04/16	546.91KB	Share
PAB	New Publication Supports Deoxymab Development		31/03/16	565.31KB	Share
PAB	Section 708A Cleansing Notice and Appendix 3B		30/03/16	686.78KB	Share
PAB	Patrys Acquires Novel Assets from Yale University	PRICE SENSITIVE	29/03/16	394.9KB	Share
PAB	Appendix 4D - Half Year Accounts - 31 December 2015	PRICE SENSITIVE	24/02/16	933.25KB	Share
PAB	Appendix 4C - Quarterly - 31 December 2015	PRICE SENSITIVE	29/01/16	50.51KB	Share
PAB	Results of Meeting		11/11/15	144KB	Share
PAB	2015 AGM Presentation		11/11/15	234.97KB	Share
PAB	Appendix 4C - Quarterly - 30 September 2015	PRICE SENSITIVE	27/10/15	95.21KB	Share
PAB	Notice of Annual General Meeting/Proxy Form		12/10/15	634.34KB	Share
PAB	2015 Corporate Governance Statement		08/10/15	297.34KB	Share
PAB	Corporate Restructure & Change in Company Secretary		30/09/15	337.1KB	Share
PAB	Market Update	PRICE SENSITIVE	29/09/15	470.85KB	Share
PAB	Response to ASX Price Query	PRICE SENSITIVE	18/09/15	555.65KB	Share
PAB	Change of Registered Office		11/09/15	332.54KB	Share
PAB	Appendix 4G		10/09/15	331.41KB	Share
PAB	Patrys 2015 Annual Report		10/09/15	1.39MB	Share
PAB	Preliminary Final Report - 30 June 2015	PRICE SENSITIVE	28/08/15	841.25KB	Share
PAB	Appendix 4C - Quarterly - 30 June 2015	PRICE SENSITIVE	14/07/15	57.74KB	Share
PAB	Copy of ASIC Form 484 - Loan Share Plan Buy Back		06/07/15	269.45KB	Share
PAB	Patrys to License Chinese Rights for PAT-SC1	PRICE SENSITIVE	25/06/15	439.32KB	Share
PAB	Manufacturing Update - Clinical Trial Remains on Hold	PRICE SENSITIVE	11/06/15	355.27KB	Share
PAB	Final share buy-back notice - Appendix 3F		19/05/15	189.04KB	Share
PAB	Daily share buy-back notice - Appendix 3E		19/05/15	196KB	Share
PAB	Announcement of buy-back - Appendix 3C		01/05/15	219.65KB	Share
PAB	Appendix 4C - Quarterly - 31 March 2015	PRICE SENSITIVE	20/04/15	156.68KB	Share
PAB	Ceasing to be a substantial holder		16/04/15	328.2KB	Share
PAB	Patrys Appoints Dr. James Campbell as CEO	PRICE SENSITIVE	08/04/15	441.93KB	Share
PAB	Appendix 4D - Half Year Accounts - 31 December 2014	PRICE SENSITIVE	25/02/15	734.43KB	Share
PAB	Patrys Granted European Patent for PAT-SM6	PRICE SENSITIVE	18/02/15	98.65KB	Share
PAB	Patrys Provides Market Update	PRICE SENSITIVE	06/02/15	90.29KB	Share

PAB Change in substantial holding
20/02/18		864.06KB	Share
PAB Section 708A Cleansing Notice and Appendix 3B
16/02/18		886.27KB	Share
PAB PAB Successfully Completes Rights Issue - Raises $2.4M
16/02/18		163.46KB	Share
PAB Rights Issue Closes Oversubscribed
14/02/18		101.55KB	Share
PAB Entitlement Offer Documents
02/02/18		96.85KB	Share
PAB Appendix 4C - Quarterly - 31 December 2017
31/01/18	PRICE SENSITIVE	306.28KB	Share
PAB Publication and Patent Filing for Humanized Version of 3E10
30/01/18	PRICE SENSITIVE	144.28KB	Share
PAB PAT-DX1-NP Localizes to Lymph Node Metastases
29/01/18	PRICE SENSITIVE	235.72KB	Share
PAB PAT-DX1 Targets Nanoparticles to Breast Cancer
29/01/18	PRICE SENSITIVE	235.96KB	Share
PAB Despatch of Entitlement Issue Offer Documents
22/01/18		1.85MB	Share
PAB Letter to Ineligible Shareholders - Entitlement Offer
16/01/18		96.98KB	Share
PAB Letter to Shareholders - Entitlement Offer
16/01/18		73.15KB	Share
PAB Letter to Option Holders - Entitlement Offer
15/01/18		97.61KB	Share
PAB Notice under Section 708AA(2)(F) - Entitlement Offer
15/01/18		186.32KB	Share
PAB Appendix 3B - Entitlement Offer
15/01/18		529.52KB	Share
PAB Entitlement Offer Booklet
15/01/18	PRICE SENSITIVE	1.79MB	Share
PAB Corporate Overview
15/01/18		1.29MB	Share
PAB $2.4 Million Fully Underwritten Rights Issue
15/01/18	PRICE SENSITIVE	151.14KB	Share
PAB Trading Halt
11/01/18	PRICE SENSITIVE	491.31KB	Share
PAB Appendix 3B - Correction
10/01/18		602.44KB	Share
PAB NDF Research - Initiation of Coverage
19/12/17		327.61KB	Share
PAB PAT-DX1 is synergistic with PARP inhibitor
11/12/17	PRICE SENSITIVE	242.61KB	Share
PAB Results of Annual General Meeting
23/11/17		409.41KB	Share
PAB Chairman's Address and CEO Presentation to 2017 AGM
23/11/17		2.57MB	Share
PAB Change in substantial holding
17/11/17		1.15MB	Share
PAB Collaboration with WEHI
16/11/17	PRICE SENSITIVE	237.83KB	Share
PAB Appendix 4C - Quarterly - 30 September 2017
27/10/17	PRICE SENSITIVE	200.91KB	Share
PAB Notice of Annual General Meeting/Proxy Form
23/10/17		829.23KB	Share
PAB Patrys Deoxymab Video Replacement
18/10/17		117.02KB	Share
PAB Patrys Video Explaining Deoxymab 3E10 Mechanism of Action
18/10/17		662.83KB	Share
PAB PAB and Garvan Institute of Medical Research Awarded Grant
16/10/17	PRICE SENSITIVE	685.46KB	Share
PAB US Patent Granted for Preclinical Candidate PAT-LM1
11/10/17	PRICE SENSITIVE	543.76KB	Share
PAB PAB Business Review - 30 June 2017
25/09/17		1.19MB	Share
PAB PAT-DX1 Conjugated to Nanoparticles, Targets Tumors
18/09/17	PRICE SENSITIVE	231.85KB	Share
PAB PAT-DX1 Active in Pre-clinical Cancer Models
14/09/17	PRICE SENSITIVE	242.9KB	Share
PAB Appendix 4G and Corporate Governance Statement
29/08/17		868.5KB	Share
PAB Appendix 4E and 2017 Annual Report
29/08/17	PRICE SENSITIVE	1.08MB	Share
PAB Appendix 4C - Quarterly - 30 June 2017
26/07/17	PRICE SENSITIVE	580.52KB	Share
PAB Change in substantial holding
25/07/17		131.87KB	Share
PAB Section 708A Cleansing Notice and Appendix 3B
17/07/17		911.13KB	Share
PAB Patrys' Deoxymab 3E10 patent granted in the U.S.
12/07/17	PRICE SENSITIVE	461.81KB	Share
PAB PAB Licences Deoxymab 3E10 - nanoparticle IP from Yale
13/06/17	PRICE SENSITIVE	247.59KB	Share
PAB Investor Update
08/06/17		708.93KB	Share
PAB Finance Update
01/05/17	PRICE SENSITIVE	323.74KB	Share
PAB Appendix 4C - Quarterly - 31 March 2017
27/04/17	PRICE SENSITIVE	172.38KB	Share
PAB Appendix 3B - Issue of Unlisted Options
19/04/17		506.06KB	Share
PAB Deoxymab 3E10 lead candidate confirmed
19/04/17	PRICE SENSITIVE	116.16KB	Share
PAB Change in substantial holding
31/03/17		1.02MB	Share
PAB Appendix 4D - Half Year Accounts - 31 December 2016
23/02/17	PRICE SENSITIVE	1.13MB	Share
PAB Appendix 4C - Quarterly - 31 December 2016
17/01/17	PRICE SENSITIVE	170.29KB	Share
PAB Change of Director's Interest Notice
22/12/16		195.54KB	Share
PAB Change of Director's Interest Notice
20/12/16		194.48KB	Share
PAB Appendix 3B
20/12/16		525.82KB	Share
PAB Final share buy-back notice - Appendix 3F
19/12/16		253.92KB	Share
PAB Daily share buy-back notice - Appendix 3E
19/12/16		225.49KB	Share
PAB Announcement of buy-back - Appendix 3C
16/12/16		240.77KB	Share
PAB Appointments to new Scientific Advisory Board
13/12/16		109.14KB	Share
PAB Results of Annual General Meeting
24/11/16		128.43KB	Share
PAB 2016 AGM Presentation
24/11/16		2.58MB	Share
PAB Appendix 4C - Quarterly - 30 September 2016-PAB.AX
28/10/16	PRICE SENSITIVE	285.35KB	Share
PAB Response to ASX Price Query-PAB.AX
27/10/16	PRICE SENSITIVE	601.55KB	Share
PAB Notice of Annual General Meeting/Proxy Form-PAB.AX
24/10/16		965.34KB	Share
PAB PAB Business Review - 30 June 2016-PAB.AX
26/09/16		896.72KB	Share
PAB Market Update-PAB.AX
13/09/16	PRICE SENSITIVE	447.92KB	Share
PAB Appendix 4G and Corporate Governance Statement-PAB.AX
30/08/16		405.92KB	Share
PAB Appendix 4E and 2016 Annual Report-PAB.AX
30/08/16	PRICE SENSITIVE	810.06KB	Share
PAB Appendix 4C - Quarterly - 30 June 2016-PAB.AX
28/07/16	PRICE SENSITIVE	100.42KB	Share
PAB Change of Director's Interest Notices x2-PAB.AX
26/05/16		46.72KB	Share
PAB Appendix 4C - Quarterly - 31 March 2016-PAB.AX
21/04/16	PRICE SENSITIVE	183.73KB	Share
PAB Publication on PAT-SM6 Combination Therapy-PAB.AX
05/04/16	PRICE SENSITIVE	546.91KB	Share
PAB New Publication Supports Deoxymab Development
31/03/16		565.31KB	Share
PAB Section 708A Cleansing Notice and Appendix 3B
30/03/16		686.78KB	Share
PAB Patrys Acquires Novel Assets from Yale University
29/03/16	PRICE SENSITIVE	394.9KB	Share
PAB Appendix 4D - Half Year Accounts - 31 December 2015
24/02/16	PRICE SENSITIVE	933.25KB	Share
PAB Appendix 4C - Quarterly - 31 December 2015
29/01/16	PRICE SENSITIVE	50.51KB	Share
PAB Results of Meeting
11/11/15		144KB	Share
PAB 2015 AGM Presentation
11/11/15		234.97KB	Share
PAB Appendix 4C - Quarterly - 30 September 2015
27/10/15	PRICE SENSITIVE	95.21KB	Share
PAB Notice of Annual General Meeting/Proxy Form
12/10/15		634.34KB	Share
PAB 2015 Corporate Governance Statement
08/10/15		297.34KB	Share
PAB Corporate Restructure & Change in Company Secretary
30/09/15		337.1KB	Share
PAB Market Update
29/09/15	PRICE SENSITIVE	470.85KB	Share
PAB Response to ASX Price Query
18/09/15	PRICE SENSITIVE	555.65KB	Share
PAB Change of Registered Office
11/09/15		332.54KB	Share
PAB Appendix 4G
10/09/15		331.41KB	Share
PAB Patrys 2015 Annual Report
10/09/15		1.39MB	Share
PAB Preliminary Final Report - 30 June 2015
28/08/15	PRICE SENSITIVE	841.25KB	Share
PAB Appendix 4C - Quarterly - 30 June 2015
14/07/15	PRICE SENSITIVE	57.74KB	Share
PAB Copy of ASIC Form 484 - Loan Share Plan Buy Back
06/07/15		269.45KB	Share
PAB Patrys to License Chinese Rights for PAT-SC1
25/06/15	PRICE SENSITIVE	439.32KB	Share
PAB Manufacturing Update - Clinical Trial Remains on Hold
11/06/15	PRICE SENSITIVE	355.27KB	Share
PAB Final share buy-back notice - Appendix 3F
19/05/15		189.04KB	Share
PAB Daily share buy-back notice - Appendix 3E
19/05/15		196KB	Share
PAB Announcement of buy-back - Appendix 3C
01/05/15		219.65KB	Share
PAB Appendix 4C - Quarterly - 31 March 2015
20/04/15	PRICE SENSITIVE	156.68KB	Share
PAB Ceasing to be a substantial holder
16/04/15		328.2KB	Share
PAB Patrys Appoints Dr. James Campbell as CEO
08/04/15	PRICE SENSITIVE	441.93KB	Share
PAB Appendix 4D - Half Year Accounts - 31 December 2014
25/02/15	PRICE SENSITIVE	734.43KB	Share
PAB Patrys Granted European Patent for PAT-SM6
18/02/15	PRICE SENSITIVE	98.65KB	Share
PAB Patrys Provides Market Update
06/02/15	PRICE SENSITIVE	90.29KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last 0.7¢		Change 0.000(0.00%)		Mkt cap ! $14.40M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
4	787620	0.8¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	981810	1

View Market Depth

No.	Vol.	Price($)
4	787620	0.008
23	9168366	0.007
14	3623680	0.006
9	3719992	0.005
7	5449000	0.004

Price($)	Vol.	No.
0.007	981810	1
0.008	1994916	4
0.009	1929459	4
0.010	251500	2
0.011	1360000	4

Last trade - 09.56am 17/05/2024 (20 minute delay)


Last 0.8¢		Change 0.000 ( 7.14 %)
Open	High	Low	Volume
0.8¢	0.8¢	0.8¢	63500
Last updated 10.24am 17/05/2024 ?

PAB (ASX) Chart

Day chart unavailable

PATRYS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available